Effect of cholesterol on the properties of spray-dried lysozyme-loaded liposomal powders.
The influence of cholesterol (Chol) in the liposomal bilayer on the properties of inhalable protein-loaded liposomal powders prepared by spray-drying technique was investigated. Lysozyme (LSZ) was used as a model protein. Feed solution for spray drying was prepared by direct mixing of aqueous solution of LSZ with mannitol solution and empty liposome dispersions composed of hydrogenated phosphatidylcholine and Chol at various molar ratios. The spray-dried powders were characterized with respect to morphology, thermal property, and crystallinity using scanning electron microscopy, differential scanning calorimetry, and X-ray diffraction, respectively. Most formulations gave slightly aggregated, spherical particles, and percentage yields of the spray-dried powders decreased with increasing Chol content. Degree of particle aggregation depended on the powder composition. The powders spontaneously formed liposomes which efficiently entrapped LSZ after reconstitution with HEPES buffered saline (HBS) at 37 degrees C. Lysozyme entrapment efficiency and size distribution of the reconstituted liposomes were evaluated after the powders were reconstituted with HBS. Increasing Chol content resulted in a decrease in size of the reconstituted liposomes and an increase in entrapment efficiency of LSZ. These results correlated with thermal behaviors of the reconstituted liposomes. Biological activity of LSZ was not affected by the spray-drying process. It was also demonstrated that LSZ-loaded liposomal powders could be produced without the need to preload the LSZ into liposomes prior to spray-drying process.
Charnvanich
Dusadee
D
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
Vardhanabhuti
Nontima
N
Kulvanich
Poj
P
D000042:Absorption; D002784:Cholesterol / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods; D004795:Enzyme Stability; D005079:Excipients / Q000737:chemistry*; D005740:Gases / Q000737:chemistry; D008081:Liposomes / Q000737:chemistry*; D008837:Micrococcus / Q000378:metabolism*; D009113:Muramidase / Q000737:chemistry* / Q000493:pharmacokinetics*; D011208:Powders
D004337:Drug Carriers; D005079:Excipients; D005740:Gases; D008081:Liposomes; D011208:Powders; D002784:Cholesterol; D009113:Muramidase
J Colloid Interface Sci. 2003 Feb 15;258(2):335-44
12618103
Drug Dev Ind Pharm. 2000 Dec;26(12):1279-84
11147128
J Control Release. 2004 Feb 10;94(2-3):259-72
14744478
J Liposome Res. 2005;15(3-4):157-66
16393907
AAPS J. 2005 Mar 24;7(1):E20-41
16146340
J Pharm Sci. 2002 Feb;91(2):482-91
11835207
Am J Physiol. 1995 Mar;268(3 Pt 1):L374-80
7900818
Biophys J. 2007 Jul 1;93(1):140-53
17434939
Eur J Pharm Biopharm. 2007 Nov;67(3):655-66
17540552
AAPS PharmSciTech. 2008;9(1):47-53
18446460
Biochim Biophys Acta. 2005 Jul 15;1713(1):57-64
15950174
Pharm Res. 1992 Apr;9(4):515-20
1495897
Eur J Pharm Biopharm. 2006 May;63(1):51-8
16380243
Biochim Biophys Acta. 1952 Mar;8(3):302-9
14934741
Biochemistry. 1987 Aug 25;26(17):5389-97
3676258
J Control Release. 2006 Jun 12;113(1):9-14
16730838
Biophys J. 2007 Aug 15;93(4):1204-14
17526577
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3001-9
17048511
Int J Pharm. 1999 Jun 25;183(2):185-93
10361169
Int J Pharm. 2004 Feb 11;270(1-2):297-306
14726144
Biochim Biophys Acta. 1976 Oct 26;457(2):109-32
184844
Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1009-29
17005293
J Control Release. 2000 Jul 31;68(1):85-95
10884582
Biochim Biophys Acta. 1988 Jun 9;947(2):367-84
3285894
Pharm Res. 1997 Sep;14(9):1151-60
9327441
Adv Drug Deliv Rev. 1997 Jun 9;26(1):51-58
10837532
Biochemistry. 1993 Jan 19;32(2):516-22
8422361
Int J Pharm. 2002 Oct 24;247(1-2):79-90
12429487
J Biol Chem. 1959 Mar;234(3):466-8
13641241
Eur J Pharm Biopharm. 2008 May;69(1):83-93
18166446